Skip to main content
S 2387 116th Congress Senate Health Business ethics Business records Civil actions and liability Competition and antitrust Congressional oversight Government ethics and transparency, public corruption Government information and archives Government studies and investigations Health care costs and insurance Health programs administration and funding Health technology, devices, supplies Inflation and prices Intellectual property Licensing and registrations Medical research Prescription drugs Public contracts and procurement Research administration and funding Research and development

We PAID Act

Introduced: July 31, 2019 Introduced by: Van Hollen, Chris Democratic · Maryland See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 31, 2019
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Jul 31, 2019
Introduced in Senate
 Plain-English summary Congressional Research Service

We Protect American Investment in Drugs Act or the We PAID Act

This bill limits the price of certain prescription drugs that rely on patents developed with federal support.

The bill requires the Department of Health and Human Services to contract with the National Academy of Medicine to conduct a study for determining the reasonableness of the price of such prescription drugs. The bill also establishes the Drug Affordability and Access Committee, which must use the study to develop a methodology and then determine whether the price of each applicable drug is reasonable after the drug enters the market.

Further, the bill establishes certain pricing requirements for such prescription drugs. First, the manufacturer must submit to the committee the list and retail prices for the drug as well as specified expenditure information. Second, after a drug is on the market for one year, the manufacture must set the drug’s list price at no more than the committee’s reasonable price determination. Third, subsequent price increases are capped at the annual percentage change in the medical care consumer price index for prescription drugs. The penalties for noncompliance with these requirements include expiration of marketing exclusivity, fines, and prohibitions on entering licensing agreements for the applicable drug.

Additionally, the bill revises the patent application requirements for drugs to include the disclosure of specified federal grants.

What's happening now July 31, 2019

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Republican 1